Hospital
Baptist Memorial Hospital- Union City INC
Baptist Memorial Hospital- Union City INC was paid $9.08M by Medicaid between Jan 2018 and Dec 2024, across 95 billing codes. Its largest line is 99284, emergency room visit (serious) — 27% of everything it billed.
33Billing provider infoBAPTIST MEMORIAL HOSPITAL- UNION CITY INC
UNION CITY, TN 38261
UNION CITY, TN 38261
33aNPI1114981768assigned 04/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.08M
24GClaims298,154
24DCodes billed95
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Tennessee
Rank by total paid#29 of 71
Median peer was paid$6.96M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DUCKETT, GREGORY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 48,324 | $1.65M | |
| 2019 | 45,293 | $1.38M | |
| 2020 | 30,915 | $834K | |
| 2021 | 44,629 | $1.26M | |
| 2022 | 48,197 | $1.61M | |
| 2023 | 43,607 | $1.17M | |
| 2024incomplete | 37,189 | $1.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 27% | 16,313 | 13,886 | $2.49M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 19,041 | 16,862 | $1.89M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 9,922 | 7,899 | $1.71M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.2% | 6,839 | 6,158 | $383K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 8,220 | 6,724 | $273K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 32,433 | 24,699 | $243K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.5% | 2,719 | 813 | $225K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.9% | 5,547 | 4,790 | $176K |
| 80053 | Comprehensive metabolic panel | 1.7% | 30,026 | 22,920 | $154K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.5% | 14,270 | 6,564 | $136K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 10,683 | 8,545 | $136K |
| 84484 | 1.4% | 8,844 | 5,345 | $127K |
83 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.1% | 7,495 | $96K |
| 36415 | Collection of venous blood by venipuncture | 1.0% | 36,407 | $93K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,756 | $88K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,339 | $75K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,619 | $66K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,285 | $62K |
| G0378 | Hospital observation service, per hour | <1% | 1,179 | $59K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,372 | $57K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 512 | $52K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,836 | $51K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,113 | $51K |
| 59025 | Fetal non-stress test | <1% | 1,759 | $51K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 584 | $42K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,146 | $36K |
| 81003 | <1% | 18,900 | $23K | |
| 83880 | <1% | 1,775 | $22K | |
| 83735 | <1% | 4,297 | $21K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 135 | $20K |
| 83690 | <1% | 2,002 | $16K | |
| 81025 | <1% | 3,220 | $15K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 604 | $14K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 399 | $11K |
| 83605 | <1% | 1,354 | $9K | |
| 85379 | <1% | 1,091 | $9K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 134 | $8K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 347 | $7K |
| 87807 | <1% | 449 | $6K | |
| 87040 | <1% | 786 | $6K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 330 | $6K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 164 | $5K |
| 85610 | <1% | 1,903 | $5K | |
| 85730 | <1% | 1,299 | $5K | |
| 73630 | <1% | 250 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 96 | $4K |
| 82150 | <1% | 398 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,954 | $3K |
| 82728 | <1% | 423 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 210 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 13 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 101 | $2K |
| 83550 | <1% | 411 | $2K | |
| 93017 | <1% | 71 | $2K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 31 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 861 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 248 | $1K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 60 | $1K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 399 | $1K |
| 83540 | <1% | 411 | $1K | |
| 74019 | <1% | 76 | $959.08 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 31 | $872.44 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,645 | $651.66 |
| 96376 | <1% | 93 | $635.58 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 16 | $567.47 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 31 | $561.51 |
| 81001 | <1% | 288 | $410.84 | |
| 82803 | <1% | 26 | $410.16 | |
| 84703 | <1% | 45 | $394.95 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 397 | $299.83 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 12 | $275.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 180 | $268.58 |
| 85027 | <1% | 20 | $264.58 | |
| 82375 | <1% | 26 | $248.82 | |
| 86140 | <1% | 43 | $232.50 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 282 | $208.89 |
| 36600 | <1% | 26 | $207.48 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 101 | $97.63 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 68 | $52.18 |
| 83050 | <1% | 26 | $51.42 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 66 | $33.83 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 179 | $26.06 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 377 | $20.49 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 34 | $18.90 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 290 | $8.10 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 131 | $0.96 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 166 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 486 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 506 | $0.00 |
| C1762 | Connective tissue, human (includes fascia lata) | 0% | 18 | $0.00 |
| A9270 | Non-covered item or service | 0% | 1,589 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 36 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 337 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 95 | $0.00 |
| 36591 | 0% | 27 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUCKETT, GREGORY (SR VP/ CLO)
Parent organizationBAPTIST MEMORIAL HEALTH CARE CORP.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.